Eversept Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$28.9M	Buy	3,039,820 +46,925	+2%	+$364K	1.91%	19
2025 Q4	$23.3M	Buy	2,992,895 +1,619,270	+118%	+$11.7M	1.31%	20
2025 Q3	$10.4M	Buy	1,373,625 +165,987	+14%	+$1.38M	0.8%	34
2025 Q2	$10.8M	Sell	1,207,638 -964,798	-44%	-$8.98M	1.09%	29
2025 Q1	$16.3M	Buy	2,172,436 +192,124	+10%	+$1.55M	1.84%	22
2024 Q4	$14.9M	Buy	1,980,312 +1,444,907	+270%	+$11M	1.54%	19
2024 Q3	$4.07M	Sell	535,405 -617,168	-54%	-$4.69M	0.31%	43
2024 Q2	$7.12M	Sell	1,152,573 -279,854	-20%	-$1.54M	0.55%	37
2024 Q1	$7.28M	Sell	1,432,427 -96,620	-6%	-$543K	0.54%	40
2023 Q4	$9.16M	Sell	1,529,047 -950,056	-38%	-$5.51M	0.9%	28
2023 Q3	$17.6M	Buy	2,479,103 +106,990	+5%	+$769K	1.95%	17
2023 Q2	$16.7M	Sell	2,372,113 -2,148,611	-48%	-$17.2M	1.76%	18
2023 Q1	$37.7M	Buy	4,520,724 +3,640,237	+413%	+$35M	3.39%	12
2022 Q4	$10.1M	Buy	+880,487	New	+$11M	0.96%	25
2021 Q1	–	Sell	-491,852	Closed	-$3.66M	–	91
2020 Q4	$3.66M	Sell	491,852 -651,359	-57%	-$3.36M	0.44%	37
2020 Q3	$3.93M	Sell	1,143,211 -3,704,581	-76%	-$15.9M	0.88%	28
2020 Q2	$23.1M	Sell	4,847,792 -2,694,580	-36%	-$10.8M	3.82%	12
2020 Q1	$15.1M	Buy	7,542,372 +2,637,912	+54%	+$7.26M	3.97%	11
2019 Q4	$16.9M	Buy	4,904,460 +4,250,000	+649%	+$10.7M	3.44%	12
2019 Q3	$1.88M	Buy	654,460 +312,000	+91%	+$970K	0.59%	38
2019 Q2	$1.3M	Sell	342,460 -70,416	-17%	-$424K	0.37%	45
2019 Q1	$3.36M	Buy	412,876 +248,917	+152%	+$2.13M	0.99%	24
2018 Q4	$1.32M	Buy	163,959 +15,000	+10%	+$117K	0.73%	29
2018 Q3	$1.14M	Hold	148,959	–	–	0.57%	33
2018 Q2	$854K	Hold	148,959	–	–	0.42%	45
2018 Q1	$711K	Sell	148,959 -49,360	-25%	-$254K	0.36%	45
2017 Q4	$974K	Buy	+198,319	New	+$961K	0.65%	31